ALUR
Allurion Technologies Inc.NYSEHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.86
P/S
0.44
EV/EBITDA
-1.61
DCF Value
$-37.12
FCF Yield
-436.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.8%
Operating Margin
-198.0%
Net Margin
-188.8%
ROE
39.1%
ROA
-182.3%
ROIC
-558.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.6M | $-6.0M | $-0.69 |
| FY 2025 | $15.2M | $-28.8M | $-3.81 |
| Q3 2025 | $2.7M | $-11.9M | $-1.53 |
| Q2 2025 | $3.4M | $-9.3M | $-1.28 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
-0.46
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.